Trending Now
  • Consumer Legal Funding Is Not Third-Party Litigation Financing, ARC Argues

EU Stakeholder Survey Aims to Inform Litigation Finance Policy

By Tom Webster |

EU Stakeholder Survey Aims to Inform Litigation Finance Policy

The following is a contributed piece by Tom Webster, Chief Commercial Officer at Sentry Funding.

An EU stakeholder survey is gathering practical information on the operation of third-party funding across the European Union. The study, ‘Mapping Third Party Litigation Funding (TPLF) in the European Union’, was given an extended deadline of 3 September 2024.

Conducted by Civic Consulting and the British Institute of International and Comparative Law (BIICL), the research will help the European Commission analyse the legal framework and practical operation of litigation funding in the EU and make policy decisions in the area.

The survey seeks views from stakeholders with experience of third-party funding, including funders, lawyers, consumer organisations, other businesses, public authorities, members of the judiciary and others. As well as questions seeking to discover the extent of funding activity in each EU jurisdiction and typical levels of investment, it also asks for views on both positive and negative effects of litigation funding.

In relation to positive effects, the survey asks a number of questions including whether respondents have observed that current litigation funding practices lead to better access to the courts for parties who could not litigate without funding; whether there is a deterrent effect on companies that serve consumer markets due to the threat of mass claims relating to unsafe products or unfair practices; and whether respondents have seen a filtering effect on claims as those with a low chance of success will not be funded.

In relation to negative effects, questions include whether respondents have observed conflicts of interest; undue influence on decisions such as settlements and appeals; and the funding of frivolous claims.

The EU survey is just one of a number of projects currently examining the litigation funding sector. Also focusing on the EU market, the European Law Institute is undertaking a substantial research project with the aim of establishing a set of principles to identify the issues that should be taken into account when entering into litigation funding agreements.

Meanwhile in the UK, the Legal Services Board recently published a report on litigation funding in England and Wales (https://legalservicesboard.org.uk/wp-content/uploads/2024/05/A-review-of-litigation-funding.pdf), and the Civil Justice Council has embarked on a wide-reaching review of the sector (https://www.judiciary.uk/related-offices-and-bodies/advisory-bodies/cjc/current-work/third-party-funding/) which will include recommendations in relation to the future regulation of the industry.

About the author

Tom Webster

Tom Webster

Commercial

View All

Defense Firms Move Into Contingency Work as Funders Supply Capital and Case Validation

Traditionally defense-oriented large law firms are increasingly taking on plaintiff-side engagements for their corporate clients, with litigation funders providing both the capital and an independent assessment of which claims merit pursuit.

As reported by Original Jurisdiction, the shift was the subject of a Burford Capital panel discussion examining how the historical division between plaintiff-side and defense-side practice has continued to erode. Corporate clients, panelists observed, have come to treat affirmative litigation as a balance sheet item rather than a cost center.

The reframing is straightforward: as one panelist put it, "if you have a meritorious legal claim, that is an asset" — one that can generate value for shareholders instead of sitting unused. Recognizing claims that way, however, requires firms built around hourly billing to absorb risk they have not historically carried.

That is where funders enter. By financing plaintiff-side matters, funders allow firms to pursue contingency work without exposing their own economics to a single outcome. Panelists also described the diligence funders perform as valuable in its own right, characterizing a funding commitment as "a vote of approval" on the strength of a claim.

The transition demands a change in orientation as much as in economics. Lawyers accustomed to defending must, in the words of one participant, "stop playing defense" and play offense, while managing budgets against work that generates no continuous hourly revenue. Larger corporate clients, meanwhile, are weighing potential recovery against the commercial relationships a claim may disturb, and selecting counsel accordingly.

Drafting Determines Whether Funding Costs Are Recoverable in Singapore Arbitration, Practitioners Warn

Whether a successful party can recover its third-party funding costs in a Singapore-seated arbitration remains unsettled and turns substantially on how the funding agreement itself is structured, according to new practitioner guidance.

As reported by Pinsent Masons, recoverability is determined by tribunals on a case-by-case basis, with no settled rule compelling or barring an award of funding costs. The threshold for challenging a tribunal's costs determination in court is correspondingly high, reflecting Singapore's minimal-intervention approach to arbitral awards.

The analysis points to the Singapore International Commercial Court's decision in *DTH v DTF*, in which the court declined to disturb a tribunal's refusal to award funding costs alongside legal costs on an award of approximately $14.73 million. The SICC observed that it was "difficult to see how such a determination could be said to shock the conscience," signaling how little room parties have to relitigate costs allocation after the fact.

Drafting is where the guidance places the emphasis. Funding agreements must satisfy the requirements of section 5B of Singapore's Civil Law Act, and arrangements framed as commercial investments in the outcome rather than as funding for the costs of proceedings risk falling foul of the maintenance and champerty rules that section 5B carves out.

The practical implication for funders and funded parties is that the recoverability question is largely settled at the point of contracting, not at the costs stage. The guidance also notes the divergence between Singapore-seated arbitration and SICC proceedings, where recovery of funding costs remains prohibited outright.

New Jersey Appellate Division Upholds Legal-Bay Medical Funding Agreement Against Statutory Challenge

New Jersey's Appellate Division has affirmed the enforceability of a Legal-Bay LLC funding agreement in *Viglianti v. Blue*, rejecting a plaintiff's argument that state insurance and lien statutes invalidated his obligation to repay the funder after his personal injury case settled.

According to PR Newswire, the underlying dispute arose after the plaintiff exhausted his automobile Personal Injury Protection benefits following a motor vehicle accident but still required spinal fusion surgery. Legal-Bay advanced $90,000 directly to his medical providers, allowing the procedure to proceed while his claim against the defendant remained pending.

After the case settled, the plaintiff challenged Legal-Bay's right to repayment, contending that New Jersey statutes governing PIP reimbursement and physician liens operated to void the funding agreement. Both the trial court and the Appellate Division disagreed. The appellate panel found that the cited statutes did not "invalidate or limit the agreement," characterizing it instead as a private contract voluntarily entered into by the plaintiff after consultation with counsel.

The decision is notable for the distinction it draws between statutory schemes regulating insurers and medical providers on one hand, and privately negotiated funding arrangements on the other. Rather than reading the PIP framework as occupying the field, the court treated the funding agreement as a separate contractual undertaking that the plaintiff was free to make.

For the consumer legal funding sector, the ruling supplies appellate-level support for medical funding structures in a state where the treatment of such arrangements has drawn recurring scrutiny. It also underscores the role documented consent and independent legal advice play when funders defend agreements against later statutory attack.